A randomised trial of the ACE inhibitor, enalapril, showed that it is possible to reduce the risk of developing heart failure in patients with asymptomatic dysfunction5 and a trial of a beta blocker, carvedilol, also showed that these drugs could be used to prevent morbidity and mortality in left ventricular dysfunction following myocardial infarction.6 Here, ACE is linked to heart failure.